Fig. 1.

a Observed and b adjusted proportions of patients with structural damage progression (CFB in mTSS > SDC) at week 52 in DAS28-group A (sustained DAS28-hsCRP ≤ 3.2 at weeks 16, 20, and 24) and DAS28-group B (DAS28-hsCRP > 3.2 or missing data at any of weeks 16, 20, and 24). Adjusted proportions (LS means) were estimated using a multivariate logistic regression model (41 patients were excluded due to missing data for covariates used in the model). Bari baricitinib, CFB change from baseline, DAS28-hsCRP Disease Activity Score for 28-joint counts based on high-sensitivity C-reactive protein, LS least squares, mTSS van der Heijde-modified total Sharp score, MTX methotrexate, SDC smallest detectable change (1.4 in the RA-BEGIN-modified intent-to-treat population)